OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Sieber on Comorbidities and the Risk of Cardiovascular Events in Prostate Cancer

May 4th 2023

Paul Sieber, MD, discusses the importance of assessing risk factors for cardiovascular events in patients with prostate cancer who are initiating androgen deprivation therapy.

Dr Son on Urinary and Bowel Anastomotic Leak in Bladder Cancer

May 4th 2023

Young Son, PGY3, discusses the future implications of findings from a study investigating the association between neoadjuvant chemotherapy and increased urinary and bowel anastomosis failure in patients with bladder cancer who are undergoing radical cystectomy.

Dr Kopetz on the Rationale of the BREAKWATER Study in BRAF V600E­mutant mCRC

May 4th 2023

Scott Kopetz, MD, PhD, FACP, discusses the rationale for launching the phase 3 BREAKWATER trial in BRAF V600E­–mutant metastatic colorectal cancer.

Dr Mohan on Toxicities Associated With T-cell–directed Therapy in Myeloma

May 4th 2023

Meera Mohan, MD, MS, FACP, discusses the toxicities associated with T-cell–directed therapies in relapsed/refractory multiple myeloma.

Dr Graff on the Investigation of Datopotamab Deruxtecan in HR+ Breast Cancer and TNBC

May 4th 2023

Stephanie L. Graff, MD, discusses current and planned investigations of the emerging antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor–positive breast cancer and triple-negative breast cancer.

Dr Patel on How the Timing of ASCT Affects Post-Transplant Complications in Myelofibrosis

May 4th 2023

Sagar Patel, MD, discusses how the timing of autologous stem cell transplant can affect outcomes in those with myelofibrosis, including the risk of patients developing post-transplant complications.

Dr Sriramareddy on the Relationship Between Uveal Melanoma and the Liver Metastases

May 3rd 2023

Sathya Neelature Sriramareddy, MD, PhD, discusses how the interaction between uveal melanoma cells and the liver microenvironment could influence metastasis growth and therapeutic response.

Dr Doonan on the Evaluation of IRAK-4 Inhibition With Emavusertib in Metastatic Brain Melanoma

May 3rd 2023

Bently P. Doonan, MD, discusses the evaluation of targeted inhibition of IRAK-4 with emavusertib in the treatment of metastatic brain melanoma.

Dr Bloomer on HRQOL Outcomes in Younger and Older Patients in CRC

May 3rd 2023

Amanda Bloomer, PhD, discusses the comparison of health-related quality of life outcomes between younger and older adult patients with newly diagnosed colorectal cancer evaluated in the ColoCare study.

Dr Bagegni on Updated APT and ATEMPT Results in Early-stage HER2+ Breast Cancer

May 3rd 2023

Nusayba Bagegni, MD, discusses updated efficacy and biomarker data from the phase 2 APT and ATEMPT trials in early-stage HER2-positive breast cancer.

Dr Hays on the Significance of the Tucatinib/Trastuzumab Approval in HER2-Positive mCRC

May 3rd 2023

John L. Hays, MD, PhD, discusses the significance of the approval for tucatinib and trastuzumab for patients with HER2-expressing metastatic colorectal cancer.

Dr Zhang on Sintilimab Plus Axitinib in FH-Deficient RCC

May 3rd 2023

Xingming Zhang discusses efficacy, safety, and quality of life findings from a phase 2 trial investigating the combination of sintilimab and axitinib in patients with fumarate hydratase–deficient renal cell carcinoma.

Dr Jones on Clinical Fracture Incidence in mHSPC

May 3rd 2023

Craig Jones, MBChB, discusses findings from an analysis of fracture incidence in patients with metastatic hormone-sensitive prostate cancer from the phase 2/3 STAMPEDE trial platform protocol.

Dr Gupta on First-line Avelumab Maintenance in Advanced Urothelial Carcinoma

May 3rd 2023

Shilpa Gupta, MD, discusses findings from a long-term analysis of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Dr Burtness on the Exploration of VIC1911 and Adavosertib in HNSCC and Lung Cancer

May 3rd 2023

Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma and lung cancer.

Dr Sahin on the Investigation of Milademetan and ONC201 in Solid Tumors

May 3rd 2023

Ilyas Sahin, MD, discusses the investigation of milademetan in combination with imipridone ONC201 as a synergistic combination in solid tumors.

Zhao on Existing Medical Conditions and Cancer Clinical Trial Enrollment

May 2nd 2023

Yayi Zhao, discusses how the prevalence of existing medical conditions and clinical factors may vary by race and effect eligibility for enrollment in clinical trials in patients with cancer.

Dr Dhanji on the Effect of Hypertension on Survival Outcomes in Upper Tract Urothelial Carcinoma

May 2nd 2023

Sohail Dhanji, MD, discusses the effect of preoperative hypertension on survival outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, and the importance of hypertension control in this population.

Dr Singer on Systemic Pembrolizumab Monotherapy in BCG-unresponsive High-Risk NMIBC

May 2nd 2023

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer.

Zamani on Disparities in Cancer Care Among Patients of Sexual/Gender Minority

May 1st 2023

Shahrzad A. Zamani, discusses the prevalence of cancer disparities in patients with cancer in sexual and gender minority populations.

NEXT PAGE
PREVIOUS PAGE